Who owns Pyxis Oncology, Inc.?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of PYXS from SEC Form 13F filings across 76 reporting managers. All positions are from one synchronized reporting period — 2026-06-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-06-30 reporting period, 76 institutions disclosed 34.2M shares of Pyxis Oncology, Inc. worth $101.1M — about 53.4% of shares outstanding; the largest disclosed holder is GordonMD Global Investments LP. Source: SEC Form 13F filings, parsed by EvidInvest.
76
13F holders
$101.1M
value, 2026 filers
53.4%
of shares outstanding (34.2M sh)
10
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-06-30 · % of fund = share of the manager's own book · % of co. = share of PYXS's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | GordonMD Global Investments LP | 10.0M | $30.2M | 14.6% | 15.7% | +143.2% |
| 2 | Pfizer Inc | 7.0M | $19.5M | 11.4% | 11% | 0.0% |
| 3 | Laurion Capital Management LP | 4.9M | $14.8M | 0.4% | 7.7% | -1.9% |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 2.1M | $6.2M | 0.0% | 3.2% | +2.1% |
| 5 | Atle Fund Management AB | 966,459 | $2.9M | 0.8% | 1.5% | +390.5% |
| 6 | BlackRock, Inc. | 867,934 | $2.6M | 0.0% | 1.4% | +10.0% |
| 7 | Palo Alto Investors LP | 864,277 | $2.6M | 0.4% | 1.4% | -14.5% |
| 8 | MARSHALL WACE, LLP | 830,544 | $2.5M | 0.0% | 1.3% | +134.3% |
| 9 | RENAISSANCE TECHNOLOGIES LLC | 772,232 | $2.3M | 0.0% | 1.2% | -13.1% |
| 10 | GEODE CAPITAL MANAGEMENT, LLC | 591,849 | $1.8M | 0.0% | 0.9% | -1.0% |
| 11 | Woodline Partners LPNEW | 523,999 | $1.6M | 0.0% | 0.8% | new |
| 12 | 683 Capital Management, LLC | 459,367 | $1.4M | 0.1% | 0.7% | -48.7% |
| 13 | JACOBS LEVY EQUITY MANAGEMENT, INC | 428,606 | $1.3M | 0.0% | 0.7% | -7.0% |
| 14 | Longaeva Partners L.P. | 353,582 | $1.1M | 0.0% | 0.6% | -29.7% |
| 15 | Decheng Capital LLC | 326,810 | $983,698 | 0.1% | 0.5% | 0.0% |
| 16 | VANGUARD FIDUCIARY TRUST CO | 302,986 | $911,988 | 0.0% | 0.5% | +0.7% |
| 17 | JANE STREET GROUP, LLC | 290,090 | $873,171 | 0.0% | 0.5% | -4.7% |
| 18 | STATE STREET CORP | 248,837 | $748,999 | 0.0% | 0.4% | 0.0% |
| 19 | MILLENNIUM MANAGEMENT LLC | 233,004 | $701,342 | 0.0% | 0.4% | -41.4% |
| 20 | UBS Group AG | 155,217 | $467,203 | 0.0% | 0.2% | -38.9% |
| 21 | Bank of New York Mellon Corp | 133,996 | $403,328 | 0.0% | 0.2% | 0.0% |
| 22 | ACADIAN ASSET MANAGEMENT LLC | 126,793 | $380,000 | 0.0% | 0.2% | -12.1% |
| 23 | NORTHERN TRUST CORP | 123,959 | $373,117 | 0.0% | 0.2% | +21.6% |
| 24 | NewEdge Wealth, LLC | 116,006 | $349,178 | 0.0% | 0.2% | 0.0% |
| 25 | XTX Topco Ltd | 110,939 | $333,926 | 0.0% | 0.2% | -44.6% |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.